Hoyland, still watching closely. Like I said when the buy side improves I'll be back on board, been stung badly by Biotechs in the past so a bit wary, yes it could cost me.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago